IMMUNOTECH-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
Apr 3 04:46 ET
IMMUNOTECH-B: PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF THE FOURTH MEMORANDUM AND ARTICLES OF ASSOCIATION
Mar 28 09:39 ET
IMMUNOTECH-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Mar 28 09:38 ET
IMMUNOTECH-B: DATE OF BOARD MEETING
Mar 18 04:52 ET
IMMUNOTECH-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024
Mar 5 07:30 ET
IMMUNOTECH-B: VOLUNTARY ANNOUNCEMENT THE CLINICAL TRIAL APPROVAL FOR THE aT19 INJECTION
Feb 19 06:32 ET
IMMUNOTECH-B: Notification Letter to Non-registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications
Feb 5 03:46 ET
IMMUNOTECH-B: Notification Letter to Registered Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications
Feb 5 03:45 ET
IMMUNOTECH-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024
Feb 2 04:20 ET
IMMUNOTECH-B: VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLED IN THE PHASE II CLINICAL TRIAL FOR CAR-T-19 INJECTION
Jan 3 06:33 ET
IMMUNOTECH-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023
Jan 3 03:40 ET
IMMUNOTECH-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
Dec 4, 2023 04:26 ET
IMMUNOTECH-B: VOLUNTARY ANNOUNCEMENT RECEIPT OF THE ACCEPTANCE NOTICE FOR THE INVESTIGATIONAL NEW DRUG APPLICATION FOR THE aT19 INJECTION
Nov 24, 2023 06:17 ET
IMMUNOTECH-B: VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLED IN THE PHASE I CLINICAL TRIAL FOR THE DENOCABTAGENE CILOLEUCEL INJECTION
Nov 7, 2023 04:30 ET
IMMUNOTECH-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2023
Nov 3, 2023 05:23 ET
IMMUNOTECH-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2023
Oct 6, 2023 04:40 ET
IMMUNOTECH-B: 2023 INTERIM REPORT
Sep 21, 2023 05:06 ET
IMMUNOTECH-B: VOLUNTARY ANNOUNCEMENT EAL WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR TREATMENT OF LIVER CANCER BY THE CENTER FOR DRUG EVALUATION
Sep 5, 2023 06:29 ET
IMMUNOTECH-B: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2023
Sep 5, 2023 04:35 ET
IMMUNOTECH-B: LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Aug 27, 2023 06:31 ET
No Data
No Data